Resultados de la búsqueda

Larrañaga-Moreira JM, Ochoa JP, Peteiro-Debén R, Martín-Álvarez E, Ripoll-Vera T, Álvarez-Rubio J, Peña-Peña ML, Llamas-Gómez H, Fernández A, Gallego-Delgado M, Rodríguez-Serrano AI, Díez-López C, Elliott PM, Palomino-Doza J, Lorca R, Limeres J, Azevedo O, Zorio E, Martín-Dorado E, Méndez-Fernández I, Franco-Gutiérrez R, de Frutos F, Escudero A, Ruiz-Guerrero L, Rodríguez-Vilela A, Mazzanti A, McKenna WJ, Barriales-Villa R; TNN Investigators. The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy. JACC Heart Fail (2025) 102419

Masri A, Maron MS, Abraham TP, Nassif ME, Barriales-Villa R, Bilen O, Coats CJ, Elliott P, Garcia-Pavia P, Massera D, Olivotto I, Oreziak A, Owens AT, Saberi S, Solomon SD, Tower-Rader A, Heitner SB, Jacoby DL, Melloni C, Wei J, Sherrid MV; REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Investigators. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail (2025) 102441

Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail (2025) Mar 31 [Epub ahead of print]

Casas G, Ródenas-Alesina E, Limeres J, Badia-Molins C, Larrañaga-Moreira JM, Mirelis JG, Navarrete-Navarro J, Martín-Jiménez J, Alcalá-López JE, González-Carrillo J, Teis A, Soler-Fernández R, Teixidó-Turà G, Gutiérrez-García L, Fernández-Álvarez P, Muñoz-Cabello P, Barrabés JA, Tirón C, Palomino-Doza J, García-Pinilla JM, Bayés-Genís A, Ripoll-Vera T, Jiménez-Jáimez J, Villacorta E, Gimeno-Blanes JR, Zorio E, García-Pavía P, Barriales-Villa R, Guala A, Petersen SE, Ferreira-González I, Rodríguez-Palomares JF. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine. Rev Esp Cardiol (2025) S1885-5857:00044-1

Cabrera-Romero E, Serrao-Faria LA, Mora-Ayestarán N, Peiró-Aventín B, Espinoza A, de Castro D, Cobo-Marcos M, Domínguez F, González-López E, Garcia-Pavia P. Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy. Amyloid (2025) 32:87-89

Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid (2025) 32:14-21

Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy J Am Heart Assoc (2025) 14:e038758
Link to the full text in Repisalud

Filamin C Registry Consortium; Gigli M, Stolfo D, Barbati G, Graw S, Chen SN, Merlo M, Medo K, Gregorio C, Dal Ferro M, Paldino A, Perotto M, Peter van Tintelen J, Te Riele ASJM, Baas AF, Wilde AM, Amin AS, Houweling AC, Elliott P, Cannie D, Michels M, Schoonvelde SAC, Prasad S, Tayal PU, Yazdani M, Morris-Rosendahl D, Garcia-Pavia P, Cabrera-Romero E, Bauce B, Pilichou K, Fatkin D, Johnson R, Judge DP, Foil KL, Heymans S, Verdonschot JAJ, Stroeks SLVM, Lakdawala NK, Anisha P, O'Neill M, Shoemaker MB, Roden DM, Calkins H, James CA, Murray B, Parikh VN, Ashley EA, Reuter C, Imazio M, Canepa M, Ameri P, Song J, Sinagra G, Taylor MRG, Mestroni L. Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants. JAMA Cardiol (2025) 10:359-369

Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Maurer MS; THAOS investigators. Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary. Future Cardiol (2025) 21:433-445

Jurcut R, Barriales-Villa R, Biagini E, Garcia-Pavia P, Olivotto I, Protonotarios A, Arbustini E, Mogensen J, Elliott P, Arbelo E, Pablo Kaski J; Members of the Task Force for the 2023 ESC Guidelines for the management of cardiomyopathies. Key priorities for the implementation of the 2023 ESC Guidelines for the Management of Cardiomyopathies in low resource settings. Eur Heart J Qual Care Clin Outcomes (2025) Mar 31 [Epub ahead of print]